Antiretroviral therapies in women after single-dose nevirapine exposure. - Wikidata - wikimedia - TriplyDB

Antiretroviral therapies in women after single-dose nevirapine exposure.

Antiretroviral therapies in women after single-dose nevirapine exposure.

http://www.wikidata.org/entity/Q34363980

about

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection Treatment of young children with HIV infection: using evidence to inform policymakers Microbicides: topical prevention against HIV Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries Effect of cotrimoxazole prophylaxis on malaria occurrence in HIV-infected patients on antiretroviral therapy in sub-Saharan Africa WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysis Standing genetic variation and the evolution of drug resistance in HIV Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009)Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study Point-of-care CD4 testing to inform selection of antiretroviral medications in south african antenatal clinics: a cost-effectiveness analysis The Global Health Impact Index: Promoting Global Health The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study.Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa.Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE)Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.Addressing standards of care in resource-limited settings.Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227 The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe.Antiretroviral treatment for children with peripartum nevirapine exposure.Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials.Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine.The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia.A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks.Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial Infant outcomes after maternal antiretroviral exposure in resource-limited settings.Transmitted drug resistance among antiretroviral-naive patients with established HIV type 1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature Frequency of Antiretroviral Resistance Mutations among Infants Exposed to Single-Dose Nevirapine and Short Course Maternal Antiretroviral Regimens: ACTG A5207.Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations

P2860

Q24235500-CF122034-6DA1-4C78-85E6-0BFF70745846 Q26864053-14FD3B9D-31F2-4110-A99D-296BC7A2D281 Q26999403-08C14197-3D5A-416A-BF85-D4D4F01B2195 Q27001286-EC8EF505-7CA3-4C10-A4E4-611E9928E7BC Q28084902-84B1D5DE-6825-4B6F-87AE-36D2E1339AA0 Q28478406-6C565A43-8C10-4983-817A-847392B05711 Q28478769-AF4717AE-D185-48BA-93B7-20F47DC7C8E4 Q28484153-FB607808-723E-45D2-B6BE-12E6C7FB4843 Q28484207-1D970045-D954-436C-B421-9D0569034960 Q28486101-3E5CBAF3-E39D-4C98-A81E-FAD51BD1B8F1 Q28488157-85986C23-7637-4EA2-8767-89871404D912 Q28543954-CB7E6220-5FDC-4BF4-AB31-1E8B652FAF2B Q28551476-21167036-6E55-4FE2-A05B-5D9A12DF835A Q28730788-E2E4B4C4-C553-4471-B1A1-14E3460127A2 Q33814942-80A40CD3-AA0D-406A-9EF1-C4A9AF8E25C9 Q33850736-AA535C5C-7A00-459C-B138-DF9A8FDF78B8 Q33944936-EF558308-D2F4-4D4B-8359-E7ABD50FE052 Q34137798-FFF6F0E1-948B-47B6-9FCA-48EA21E81308 Q34200009-42BDA20F-FFFE-47EC-AD77-816E880E1E67 Q34214090-58677F19-9672-4695-B081-FDF6B1A5D8DB Q34338893-E522C805-75FA-4C0B-955B-57F2E2F4720B Q34433397-E95CEC9B-B3BC-42FD-AA86-CD7AA70AB0DF Q34469240-5E8A2046-82A2-4B3B-8FD5-D02F83F7614F Q34494986-2A4B6FB0-CBCB-459D-B26E-E5C8683ECF2F Q35014739-7F910E29-24AA-49BE-BFE1-1B29E130A3A7 Q35021860-702AB82C-04B0-4886-A3BA-07615073EA03 Q35111300-D69A81D7-D7A8-4764-9652-C6B93A1C7129 Q35145366-6747A4A4-298A-4F0E-A9DC-2007D6A68CB2 Q35388475-904D1AF4-287C-413D-AF93-2DDED9B1AAB9 Q35549179-0362B6D9-A1A9-43D5-A1A2-284D038D3DCA Q35632898-19971161-E4F7-4157-9B91-301244613EEA Q35770848-5F63485E-DED8-49DD-88EC-F8B88CEE03EB Q35771321-47CF969E-5504-47EA-83DC-A34E9BD4FBD3 Q35949791-33B71E0D-1FA5-4D8F-98E7-A0B7D5286AF3 Q35965440-CC02BE96-00A2-45F3-A794-564A16A1DFAA Q35996783-02684CF0-3DF4-408B-BEF8-FE3490DEA2EC Q36050107-EDA8CB22-130B-4DAE-9D35-5B4AE8249A76 Q36223682-4A19FB58-BDF2-46D4-AE11-3196821B732C Q36238419-C80652F1-5670-4F2A-B5B6-5C7F062FB955 Q36410952-9D016566-757B-49E3-9F62-F2681AA3EFD7

P2860

Antiretroviral therapies in women after single-dose nevirapine exposure.

http://www.wikidata.org/entity/Q34363980

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Antiretroviral therapies in women after single-dose nevirapine exposure.

@ast

Antiretroviral therapies in women after single-dose nevirapine exposure.

@en

Antiretroviral therapies in women after single-dose nevirapine exposure.

@nl

type

label

Antiretroviral therapies in women after single-dose nevirapine exposure.

@ast

Antiretroviral therapies in women after single-dose nevirapine exposure.

@en

Antiretroviral therapies in women after single-dose nevirapine exposure.

@nl

prefLabel

Antiretroviral therapies in women after single-dose nevirapine exposure.

@ast

Antiretroviral therapies in women after single-dose nevirapine exposure.

@en

Antiretroviral therapies in women after single-dose nevirapine exposure.

@nl

P1433

Q34363980-F5C0CBB5-37AC-4ACB-B6D2-54856CAD29EF

P1476

Q34363980-8D0AD55A-5F22-4774-9D58-6F1004471D1D

P2093

Q34363980-150A941A-6F2D-40F9-A5DC-C41F5285A57E

Q34363980-1D256F45-8419-4B68-8ED0-19CC1138129E

Q34363980-2F4D9048-79D3-4EBA-9476-A6B1C887A870

Q34363980-3139D94D-7D51-43F1-ABDF-4992517CAFDE

Q34363980-36973D52-11B1-405E-823E-753AFDD5CB1D

Q34363980-38AFB286-D2E5-4655-A8AD-06710693BAF5

Q34363980-406FD4C9-D00C-40FA-AFB9-61294E0E811A

Q34363980-5909EAD7-1185-4E89-8BD1-0D395D9F68D8

Q34363980-62208F9C-771B-4460-BF95-395140EF8854

Q34363980-62FDA8EF-2B6E-4AC4-B19E-E69E8E673F47

P2860

Q34363980-0A76578C-906D-47A9-B734-BB9B46B55996

Q34363980-16582FA4-6574-4FD2-A7B8-2BCDE1910512

Q34363980-2234C56F-1691-47CA-8565-28820E2A4AD2

Q34363980-27752784-4FC8-453C-9D66-C8914019D2D4

Q34363980-2CA567E2-5C09-45FB-AA64-53F1A3037C0C

Q34363980-41FFD617-A50C-4C1A-972A-809173436A46

Q34363980-4822C73D-C512-4143-AF16-BC2B578C3DF9

Q34363980-4DC32FC1-3EEE-4265-ADF1-CDDFBD335AE1

Q34363980-521165C7-881A-4781-A58C-8DD9FFF53F4F

Q34363980-52BA9E1E-F24C-4C19-AC8D-D2A7DCB403AE

P304

Q34363980-B960957B-B8CE-4819-9D59-4BB29CBEC122

P31

Q34363980-ABAE63D3-C301-4A36-AE51-4967C38CDEEB

P356

Q34363980-8DFA9FC3-67B5-42B0-82A9-4FB64D14672C

P407

Q34363980-A7EC563E-5367-471A-9F5A-D771DB670951

P433

Q34363980-7775A5F0-8141-492C-BB34-41C555643F92

P478

Q34363980-7473A694-A44E-4978-8A6A-00EDC7D296D4

P50

Q34363980-2110B6A9-6362-483F-8CDB-6E4526F62449

Q34363980-A067033F-6559-49F8-B52F-C7AE5E837248

Q34363980-C8D0A07C-AA5A-40E4-B2F0-3DCF3D0B0D65

Q34363980-F60B94D2-9F39-400B-ADED-7C732797D0DE

P577

Q34363980-1BF21A55-A467-45EC-899A-D75D5B7ED5D2

P698

Q34363980-A85E51D2-D012-415A-95E3-3B892E23ADD7

P921

Q34363980-A932BD1F-73C7-4088-97AC-5749E3D67372

P932

Q34363980-86D7216F-7B91-4AF6-B053-5BDC67D213C3

P356

P1433

The New England Journal of Medicine

P1476

Antiretroviral therapies in women after single-dose nevirapine exposure.

@en

P2093

Abraham Siika

http://www.w3.org/2001/XMLSchema#string

Aida Asmelash

http://www.w3.org/2001/XMLSchema#string

Ann Walawander

http://www.w3.org/2001/XMLSchema#string

Beverly Alston-Smith

http://www.w3.org/2001/XMLSchema#string

Cecilia Kanyama

http://www.w3.org/2001/XMLSchema#string

Diana Atwine

http://www.w3.org/2001/XMLSchema#string

Douglas Shaffer

http://www.w3.org/2001/XMLSchema#string

Elizabeth Stringer

http://www.w3.org/2001/XMLSchema#string

Eva Purcelle-Smith

http://www.w3.org/2001/XMLSchema#string

Evelyn Hogg

http://www.w3.org/2001/XMLSchema#string

P2860

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study

Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial

Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.

Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.

Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.

Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.

Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

P304

1499-1509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0906626

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

363

http://www.w3.org/2001/XMLSchema#string

P50

Kara Wools-Kaloustian

Tsungai Chipato

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20942666

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

2994321

http://www.w3.org/2001/XMLSchema#string